Paper Contents
Abstract
The alarming rise of multi-drug resistant (MDR) pathogens has triggered a global healthcare crisis, necessitating innovative and effective alternatives to conventional antibiotics. Cold atmospheric plasma (CAP) has emerged as a promising non-antibiotic approach to inactivate MDR bacteria and disrupt biofilms, which are major contributors to persistent infections. This paper explores the mechanisms, efficacy, and clinical potential of plasma treatment in combating MDR pathogens. We discuss plasma-generated reactive species, their interactions with bacterial cells, biofilm degradation, and emerging applications in clinical microbiology. The review also highlights challenges and future prospects for integrating plasma technologies into mainstream antimicrobial therapies.
Copyright
Copyright © 2025 Punit Kumar. This is an open access article distributed under the Creative Commons Attribution License.
